Background and Importance Immunisation is the best prevention against pneumococcal diseases in people living with HIV (PLHIV). From 2010 to 2022, the recommended vaccination schedule was sequential: 13v conjugate vaccine followed by the 23v polysaccharide vaccine.

Aim and Objectives The aim of the study was to describe and compare vaccine coverage against pneumococcus before and after the COVID-19 pandemic in (PLHIV).

Material and Methods The sample was obtained from patients who attended the Pharmacy Department of a tertiary hospital in the years 2019 and 2022 to receive their antiretroviral drugs. Vaccination data were obtained from the SISPAL database of the Community of Madrid. Vaccination coverage between 2019 and 2022 was estimated and compared using bivariate logistic regression.

Results In total, PLHIV were 2,978 and 3,169 in 2019 and 2022 respectively. The median age was 47 (37–53) and 46 (35–53) respectively. Men were more prevalent, with 81.5% in 2019 and 81.9% in 2022. 62.7% and 68.5% received the sequential anti-pneumococcal regimen in 2019 and 2022, respectively (OR 1.29 95%; CI: 1.13–1.48; p<0.05). 29.6% (2019) and 22.6% (2022) of the patients did not complete the sequential vaccine regimen, and 7.7% (2019) and 8.9% (2022) did not receive any vaccine in both years.

Conclusion and Relevance Vaccine coverage in people living with HIV against pneumococcus increased in 2022 compared to 2019, prior to the COVID-19 pandemic.

Conflict of Interest No conflict of interest.